Androgen effect on prostate specific antigen secretion
β Scribed by Dr. Kamal A. Hanash; Kash F. Mostofi
- Publisher
- John Wiley and Sons
- Year
- 1992
- Tongue
- English
- Weight
- 271 KB
- Volume
- 49
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Prolonged parenteral androgen therapy for 1 year resulted in the hypersecretion of prostate specific antigen (PSA) in a patient with no clinical evidence of prostatic carcinoma, who had been treated with diethylstilbestrol (DES) for 9 years. The PSA level declined to normal values upon temporary discontinuation of androgen therapy and increased again upon resumption of treatment. This case seems to confirm the regulatory effect of androgens of PSA secretion and to suggest a possible βreboundβ elevation of PSA in patients with androgen deprivation treated with testosterone replacement. The estrogen suppressed prostatic epithelial cells were able to respond to androgen stimulation with a steady increase in the PSA secretion and positive immunohistochemical PSA staining.
π SIMILAR VOLUMES
## Abstract Prostate specific antigen (PSA) is a serine protease that is synthesized by both normal and malignant epithelial cells of the human prostate. PSA expressed by malignant cells, however, are released into the serum at an increased level, which can be detected to diagnose and monitor prost
Previous studies have suggested that serum prostate-specific antigen (PSA) levels are under androgenic influence, especially in patients with adenocarcinoma of the prostate. PSMA (prostate-specific membrane antigen) is thought to reflect hormonal or clonal resistance or an independence with respect
## Abstract Androgens regulate the expression of both human prostatic acid phosphatase (PAcP) and prostateβspecific antigen (PSA), two major prostate epitheliumβspecific differentiation antigens. Due to the important role of these two enzymes as prostate epithelium differentiation markers, we inves
## Abstract ## BACKGROUND Increasing body mass index (BMI) is associated with shorter time to prostateβspecific antigen (PSA) failure after radical prostatectomy. Whether BMI is associated with time to PSA failure was investigated in men treated with androgen suppression therapy (AST) and radiatio